Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Authors
Regan, MNeven, P
Giobbie-Hurder, A
Goldhirsch, A
Ejlertsen, B
Mauriac, L
Forbes, J
Smith, I
Láng, I
Wardley, Andrew M
Rabaglio, M
Price, K
Gelber, R
Coates, A
Thürlimann, B
Affiliation
International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.Issue Date
2011-11
Metadata
Show full item recordAbstract
Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up.Citation
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. 2011, 12 (12):1101-8 Lancet OncolJournal
Lancet OncologyDOI
10.1016/S1470-2045(11)70270-4PubMed ID
22018631Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(11)70270-4